What Should Investors Know About Globus Medical (GMED) Stock?

Join us for a quick overview of Globus Medical, a Medical Instruments & Supplies company whose shares moved -1.1% today. Here are some facts about the stock that should help you see the bigger picture:

  • Globus Medical has moved -19.0% over the last year, and the S&P 500 logged a change of 13.0%

  • GMED has an average analyst rating of buy and is -23.45% away from its mean target price of $66.36 per share

  • Its trailing earnings per share (EPS) is $2.07

  • Globus Medical has a trailing 12 month Price to Earnings (P/E) ratio of 24.5 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $2.59 and its forward P/E ratio is 19.6

  • The company has a Price to Book (P/B) ratio of 2.57 in contrast to the S&P 500's average ratio of 2.95

  • Globus Medical is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16

  • GMED has reported YOY quarterly earnings growth of 7.5% and gross profit margins of 0.7%

  • The company has a free cash flow of $90.91 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.